Clinical trials: Solid Cancers
Advanced Solid Tumor
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult…
- Trial name
- NCT05021367
- Testing
- TQB3823 tablets
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Japanese Phase 1 Study of BMS-844203 (CT322)
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
- Trial name
- NCT01146171
- Testing
- BMS-844203 (CT-322)
- Where
- Japan
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Solid Cancers
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT01075464
- Testing
- MEGF0444A, bevacizumab, paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
This is a phase Ib/II study to evaluate the safety, tolerability, PK profile and preliminary efficacy of fruquintinib monotherapy or plus sintilimab for advanced solid tumors.
- Trial name
- NCT03903705
- Testing
- Fruquintinib in Combination with Sintilimab
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Hutchmed
Cancer
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).
- Trial name
- NCT00993239
- Testing
- Birinapant (TL32711)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- TetraLogic Pharmaceuticals
Solid Tumors, Adult
A Study of GC203 TIL in Advanced Solid Tumors (NF)
This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
- Trial name
- NCT07256756
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Juncell Therapeutics
Solid Tumor
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
- Trial name
- NCT03757936
- Testing
- HLX04, HLX10
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Henlius Biotech
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors, Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not…
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT04337177
- Testing
- VAL-413, Temozolomide
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Valent Technologies, LLC
Solid Tumors, Adult
Study of ON 123300 in Patients With Advanced Cancer
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
- Trial name
- NCT04739293
- Testing
- ON123300
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
Colorectal Cancer, Lung Cancer
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice.
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer
- Trial name
- NCT00054977
- Testing
- GM-CT-01, 5-fluorouracil
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Galectin Therapeutics Inc.
Metastatic Malignant Neoplasm
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response.
- Trial name
- NCT06240728
- Testing
- NPX887
- Where
- 8 sites in United States, South Korea
- Volunteers
- 144 people
- Sponsor
- NextPoint Therapeutics, Inc.
Advanced Solid Tumor
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.
- Trial name
- NCT02836600
- Testing
- LY3039478
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumours
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours.
- Trial name
- NCT02430311
- Testing
- Olaparib, Paclitaxel
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Open label, single- and multiple-dose administration, dose-exploratory clinical phase I study to evaluate the safety, tolerability and PK profile of HX301 monolactate capsules in patients with advanced malignant solid tumors and…
- Trial name
- NCT05731934
- Testing
- HX301
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.
Solid Tumor
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
- Trial name
- NCT02216409
- Testing
- Hu5F9-G4
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Gilead Sciences
Neoplasms
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
This is a first time in human (FTIH), open-label, non-randomized, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of GSK3174998…
- Trial name
- NCT02528357
- Testing
- GSK3174998, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Pancreatic Adenocarcinoma
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
- Trial name
- NCT03592264
- Testing
- OBI-3424
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- OBI Pharma, Inc